Mobile

A twelve-week, randomized, double-blind, multi-center, placebo controlled, parallel group study to evaluate the safety and efficacy of aliskiren 150 mg when added to standard therapy in patients with ...

Update Il y a 4 ans
Reference: EUCTR2004-004014-16

A twelve-week, randomized, double-blind, multi-center, placebo controlled, parallel group study to evaluate the safety and efficacy of aliskiren 150 mg when added to standard therapy in patients with stable heart failure

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

• Evaluate the overall safety and tolerability of aliskiren 150 mg when given in addition to standard therapy in hypertensive patients with stable heart failure.

Inclusion criteria

  • Hypertension

Links